Does the aldosterone:renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study

TY - JOUR

T1 - Does the aldosterone:renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension?

T2 - A clinical trial protocol for RENALDO (RENin-ALDOsterone) study

AU - Parthasarathy, Hari K.

AU - Alhashmi, Khamis

AU - McMahon, Alex D.

AU - Struthers, Allan D.

AU - Connell, John M. C.

AU - McInnes, Gordon T.

AU - Ford, Ian

AU - MacDonald, Thomas M.

PY - 2007

Y1 - 2007

N2 - High blood pressure is an important determinant of cardiovascular disease risk. Treated hypertensives do not attain a risk level equivalent to normotensives. This may be a consequence of suboptimal blood pressure control to which indiscriminate use of antihypertensive drugs may contribute. Indeed the recent ALLHAT1study suggests that thiazides should be given first to virtually all hypertensives. Whether this is correct or whether different antihypertensive therapies should be targeted towards different patients is a major unresolved issue, which we address in this study. The measurement of the ratio of aldosterone: renin is used to identify hypertensive subjects who may respond well to treatment with the aldosterone antagonist spironolactone. It is not known if subjects with a high ratio have aldosteronism or aldosterone-sensitive hypertension is debated but it is important to know whether spironolactone is superior to other diuretics such as bendroflumethiazide in this setting.

AB - High blood pressure is an important determinant of cardiovascular disease risk. Treated hypertensives do not attain a risk level equivalent to normotensives. This may be a consequence of suboptimal blood pressure control to which indiscriminate use of antihypertensive drugs may contribute. Indeed the recent ALLHAT1study suggests that thiazides should be given first to virtually all hypertensives. Whether this is correct or whether different antihypertensive therapies should be targeted towards different patients is a major unresolved issue, which we address in this study. The measurement of the ratio of aldosterone: renin is used to identify hypertensive subjects who may respond well to treatment with the aldosterone antagonist spironolactone. It is not known if subjects with a high ratio have aldosteronism or aldosterone-sensitive hypertension is debated but it is important to know whether spironolactone is superior to other diuretics such as bendroflumethiazide in this setting.

U2 - 10.1186/1471-2261-7-14

DO - 10.1186/1471-2261-7-14

M3 - Article

C2 - 17490489

VL - 7

SP - 14

JO - BMC Cardiovascular Disorders

JF - BMC Cardiovascular Disorders

ER -